Edgewise Therapeutics, Inc. (EWTX) Operating income 2020–2025
Edgewise Therapeutics, Inc. (EWTX) annual operating income history from SEC filings — each fiscal year as reported.
-$191.4MFY2025 · since FY2020: -$17.2M → -$191.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$191.4M | -20.5% |
| FY2024 | -$158.8M | -38.9% |
| FY2023 | -$114.4M | -59.6% |
| FY2022 | -$71.7M | -65.8% |
| FY2021 | -$43.2M | -151.4% |
| FY2020 | -$17.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More EWTX financial trends
EWTX RevenueEWTX Net incomeEWTX Net marginEWTX Gross profitEWTX Gross marginEWTX Operating marginEWTX Operating cash flowEWTX Free cash flowEWTX Capital expendituresEWTX Return on equityEWTX Stock buybacksEWTX Dividends paidEWTX Total assetsEWTX Total liabilitiesEWTX Shareholders’ equityEWTX overview →